Anorexia is a type of eating disorder that is characterized by distortion of body image, intense fear of gaining weight, and extremely disturbed eating behaviour. Symptoms of anorexia can include low body weight, lack of menstruation among girls and women, severe food restriction, low blood pressure, brain damage, severe constipation, multi-organ failure and infertility. According to researchers, the risk factors associated with anorexia can be psychological, social, biological, behavioural, and genetic factors. Anorexia can be treated by psychotherapy, nutritional counselling, and medications such as anti-depressants and mood stabilizers. The University of Erlangen-Nürnberg Medical School is in the process of developing ethinyl estradiol for the treatment of anorexia. RaQualia Pharma, Inc. is in the process of developing RQ-00433412 as a ghrelin receptor agonist for the treatment of anorexia. Some of the companies and universities having the pipeline of anorexia include University of Erlangen-Nürnberg Medical School, Specialised Therapeutics, RaQualia Pharma, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.